Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine

Zhi-duo Hou¹, Zheng-yu Xiao¹, Yao Gong¹, Yu-ping Zhang¹ and Qing Yu Zeng²*

Abstract

Background: Polymorphisms of Arylamine N-acetyltransferase (NAT) that contribute to diverse susceptibilities of some autoimmune diseases are also linked to the metabolism of several drugs including sulfasalazine (SSZ). The aim of this study was to investigate the distribution of NAT polymorphisms in Han Chinese patients with ankylosing spondylitis (AS) and their correlation to sulfasalazine-induced adverse drug reactions (ADRs).

Methods: Arylamine N-acetyltransferase 1 (NAT1) and arylamine N-acetyltransferase 2 (NAT2) genotypes were determined in 266 AS patients who received SSZ treatment and 280 healthy controls. The correlation between NAT polymorphisms and SSZ-induced ADRs was analyzed.

Results: The co-occurrence frequency of NAT2 fast acetylator genotype and NAT1*10/NAT1*10 genotype was lower in AS patients than in controls. No positive correlations were detected between NAT polymorphisms and AS clinical features. The prevalence of SSZ-induced ADRs and drug withdrawal was 9.4% and 7.1%, respectively. The frequencies of overall ADRs, dose-related ADRs, and termination of drug treatment because of intolerance were higher in the NAT2 slow acetylator genotype carriers than in the fast-type carriers and in those with co-existence of NAT1 and NAT2 slow acetylator genotypes. Furthermore, the ADRs emerged earlier in the AS cases carrying both NAT1 and NAT2 slow acetylator genotypes.

Conclusions: The prevalence of co-occurring NAT2 fast acetylator genotype and NAT1*10/NAT1*10 genotype was lower in AS patients than in controls. The NAT2 slow acetylator genotype and co-existing NAT1 and NAT2 slow acetylator genotypes appear to be associated with higher risks of SSZ-induced ADRs.

Keywords: Arylamine N-acetyltransferases, Genetic polymorphism, Sulfasalazine, Ankylosing spondylitis, Adverse drug reactions

Background

Sulfasalazine (SSZ) is one of the disease-modifying anti-rheumatic drugs (DMARDs) and has been widely used for the treatment of ankylosing spondylitis (AS) in China for years [1]. Though the efficacy of SSZ in treating AS is still under debate, Chinese rheumatologists prefer to prescribe SSZ for the treatment of AS because of its good cost-effectiveness ratio. Nevertheless, the therapy is often terminated in about 14–38% of AS patients receiving SSZ treatment because of adverse drug reactions (ADRs) [2-4]. There is currently no effective method of identifying a patient’s susceptibility to SSZ-induced ADRs. Thus, predicting the therapeutic response of AS patients to SSZ is of great importance for individualized therapies of AS.

SSZ is constituted by 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP). SP is considered to be an active component for the therapy of AS [5], and is related to ADRs such as nausea, vomiting, and headache [6], while 5-ASA is effective for the treatment of inflammatory

* Correspondence: qyzeng@stu.edu.cn
²Research Unit of Rheumatology, Shantou University Medical College, No.22 Xin Ling Road, Shantou 515041, Guangdong Province, China
Full list of author information is available at the end of the article
bowel disease and is related to ADRs such as diarrhea [7]. When orally administered, SSZ is metabolized into SP and 5-ASA in the presence of the gut microbiota [8,9]. SP is almost completely absorbed and metabolized to N-acetyl-SP predominantly by hepatic arylamine N-acetyltransferase 2 (NAT2), while only about 20–30% of 5-ASA is absorbed and metabolized to N-acetyl-5-ASA by arylamine N-acetyltransferase 1 (NAT1), the rest being eliminated in the feces [9,10]. Therefore, arylamine N-acetyltransferases (NATs) play an important role in the metabolism of SP and 5-ASA.

Humans have two functional NAT genes (NAT1 and NAT2) and a pseudogene (NATP), all found on chromosome 8p22 [11]. Genetic mutations of NAT1 and NAT2 result in amino acid substitutions of their protein products, and may lead to altered gene expression and activity of the NAT enzyme [11-14]. These changes were shown to contribute to increased susceptibility to a range of disorders including autoimmune diseases [15-20] and carcinomas [21-24], but were also linked to the differences in the ability to N-acetylate certain drugs including SSZ [6,10,25-29]. In this study, we investigated the genotypes of the NAT enzyme [11-14]. These changes were shown to contribute to increased susceptibility to a range of disorders including autoimmune diseases [15-20] and carcinomas [21-24], but were also linked to the differences in the ability to N-acetylate certain drugs including SSZ [6,10,25-29]. In this study, we investigated the genotypes of the two human NATs in Han Chinese patients with AS versus healthy controls and also the potential correlation of the two human NATs in Han Chinese patients with AS versus healthy controls.

**Methods**

**Subjects**

Two hundred and sixty-six consecutive cases of AS from the First Affiliated Hospital of Shantou University Medical College were studied during the period of 2004–2010. All patients were diagnosed based on the Modified New York Criteria of AS [30]. All patients were treated with SSZ at a dose of 1.5–3.0 g/day (Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd, China). Non-steroidal anti-inflammatory drugs were prescribed as needed. Two hundred and eighty healthy volunteers served as the healthy controls. All subjects were Han Chinese residing in Shantou, China. This study was approved by the Institutional Ethics Committee of Shantou University Medical College, and written informed consent was obtained from all participants.

**Determination of NAT genetic polymorphisms**

Genomic DNA was extracted from peripheral blood samples with the QIAamp Blood Kit (QIAGEN, Hilden, Germany) and stored at −80°C. Genetic polymorphisms of NAT1 (NAT1*4, NAT1*3, NAT1*10, NAT1*11) and NAT2 (NAT2*4, NAT2*5, NAT2*6, NAT2*7) were determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method [24,31]. The NAT genotypes of a number of samples were confirmed through direct DNA sequencing for quality control purposes. Subjects were classified as NAT1 fast acetylator genotype carriers (those with at least one NAT1*10 allele) or NAT1 slow acetylator genotype carriers (those without NAT1*10 allele) [24]. Individuals carrying at least one wild-type allele (NAT2*4 allele) were classified as NAT2 fast acetylator genotype carrier, and those carrying the mutant allele (NAT2*5, *6, *7) were classified as NAT2 slow acetylator genotype carriers [32].

**Observation of clinical features**

Clinical features observed included age of onset, duration of disease, joint involvement (classified into two types: axial joint involvement only, and both axial and peripheral joint involvements), incidence of radiological hip involvement, and HLA-B27 status.

**Assessment of ADRs**

All patients were followed up for more than 2 years and SSZ-induced ADRs were monitored. ADRs and severe ADRs were defined according to the criteria proposed by Edwards et al. [33]. ADRs were classified into six types: dose-related (Augmented), non-dose-related (Bizarre), dose-related and time-related (Chronic), time-related (Delayed), withdrawal (End of use), and failure of therapy (Failure). The causality assessment of suspected ADRs was determined as described previously [33]. ADRs were classified as being “certain”, “probable”, “possible”, “unlikely”, “conditional”, and “unassessable”. All ADRs noted in this study were “certain”, “probable”, or “possible”.

**Statistical analysis**

Data were analyzed using SPSS 19.0 statistical software. Departure from the Hardy-Weinberg equilibrium was tested by the chi-squared test. Frequencies of the alleles, genotypes, acetylator genotypes, and co-occurrence of NAT1 with NAT2 acetylator genotypes in each group were compared using chi-squared test or the Fisher’s exact test as appropriate. All ADRs in each group was compared using the Fisher’s exact test as appropriate. Age of onset and duration of disease in each group were compared using t-test, one-way ANOVA test or Kruskal Wallis test as appropriate. Odds ratio (OR) and a 95% confidence interval (95% CI) were estimated from logistic regression models to test for associations between the risk of SSZ-induced ADRs and the NAT acetylator genotypes. Binary logistic regression analysis was used to identify the variables (NAT acetylator genotype, dose, age, sex, and NSAIDs combination) that provided an important contribution towards the variability of SSZ-induced ADRs and to adjust for confounding variables by analysis of covariates. The prevalence of drug treatment termination because of SSZ-induced ADRs in each group was compared using the chi-squared test or the Fisher’s exact test as appropriate. Differences in the duration of ADRs occurring in each group were compared using the Mann–Whitney U test. *P* < 0.05 was considered statistically significant.
Results

Subject characteristics

Of the AS patients, 219 were male and 47 were female. The positive rate of HLA-B27 in patients was 90.2%. The mean age was 27.8 ± 9.1 years and the mean disease duration was 6.8 ± 5.7 years. The control group included 221 male and 59 female healthy volunteers with a mean age of 35.1 ± 10.0 years.

NAT polymorphisms in AS patients and healthy controls

The distribution of NAT1 and NAT2 gene polymorphisms in AS patients and healthy controls is shown in Table 1. The allele frequencies of both AS patients and healthy controls were consistent with the Hardy–Weinberg equilibrium (P > 0.05). No significant differences between the AS and control group were found for the distribution of alleles, genotypes, and acetylator genotypes when NAT1 and NAT2 polymorphisms were analyzed independently. However, the co-occurrence frequency of the NAT2 fast acetylator genotype and NAT1*10/NAT1*10 genotype was lower in AS patients than in controls (6.4% vs 11.4%, P = 0.04, OR = 0.53, 95% CI 0.29–0.98).

Correlations between NAT polymorphisms and clinical features of AS

The age of onset, duration of disease, joint involvement types, incidence of radiological hip involvement, and the positive rate of HLA-B27 were not significantly different in each NAT genotype or NAT acetylator genotype group among the AS patients (P > 0.05).

SSZ-induced ADRs

SSZ-induced ADRs occurred in 25 cases (9.4%) of AS (Table 2). Among these, 16 patients (64.0%) experienced dose-related ADRs; eight patients (32.0%) experienced non-dose-related ADRs, and one patient (4.0%) experienced time-related ADR. The dose-related ADRs observed in this study included nausea, anorexia, abdominal pain, diarrhea, epigastric discomfort, dizziness, elevation of serum liver enzyme levels, and chest congestion. Non-dose-related ADRs included rash, oral ulcer, and leukopenia. One patient with cacospermia was classified as having time-related ADR. No serious ADRs were found in the AS group of patients. SSZ therapy was terminated because of SSZ-induced ADRs in 19 AS patients (7.1%). Of these, 10 patients (52.6%) withdrew from SSZ therapy because of dose-related ADRs; eight patients (42.1%) because of non-dose-related ADRs, and one patient (5.3%) because of time-related ADR. The mean duration of SSZ therapy from the time when the first ADR occurred was 19 days (range 3–450 days). Most ADRs occurred within 12 weeks after the start of SSZ treatment (23 cases, 92.0%).

Correlations of NAT polymorphisms and SSZ-induced ADRs

Correlations between NAT acetylator genotypes and SSZ-induced ADRs are shown in Table 3. The incidence of overall ADRs in patients carrying the NAT2 slow acetylator genotype was 18.5% (10/54) and was significantly higher than patients carrying the NAT2 fast acetylator genotype (7.1%, 15/212, P = 0.013, OR = 2.99, 95% CI 1.26–7.09). The incidence of dose-related ADRs in patients carrying the NAT2 slow acetylator genotype was higher also than in patients carrying the fast acetylator genotype (16.7% vs 3.3%, P = 0.002, OR = 5.17, 95% CI 1.79–14.92). No significant difference in the incidence of non-dose-related ADRs was found between the NAT2 fast and NAT2 slow acetylator genotype groups (3.3% vs 1.9%, P > 0.05). The prevalence of drug treatment termination owing to ADRs or dose-related ADRs was higher in the NAT2 slow acetylator genotype carriers than in the fast-type carriers (14.8% vs 5.2%, P = 0.032 and 13.0% vs 1.4%, P = 0.001, respectively).

The incidences of overall ADRs, dose-related ADRs, and non-dose-related ADRs in patients carrying the NAT1 fast acetylator genotype were 8.1% (11/136), 4.4% (6/136), and 3.7% (5/136) respectively, similar to 10.8% (14/130), 7.7% (10/130), and 2.3% (3/130) in patients carrying the NAT1 slow acetylator genotype (P > 0.05). The prevalence of drug treatment termination owing to overall ADRs or dose-related ADRs was slightly higher in the NAT1 slow acetylator genotype carriers than in the fast-type carriers (8.5% vs 5.9%, and 5.4% vs 2.2%, respectively). However, the difference was not significant (P > 0.05).

The incidences of both overall ADRs and dose-related ADRs were higher in patients carrying both the NAT1 slow acetylator genotype and the NAT2 slow acetylator genotype than in the other carriers (26.3% vs 6.6%, P < 0.001, OR = 5.07, 95% CI 2.08–12.37 and 23.7% vs 3.1%, P < 0.001, OR = 9.52, 95% CI 3.20–28.30). The prevalence of drug treatment termination owing to overall ADRs or dose-related ADRs was also higher in the carriers of both NAT1 slow acetylator genotype and NAT2 slow acetylator genotype than in the other carriers (21.1% vs 4.8%, P = 0.002 and 18.4% vs 1.3%, P < 0.001, respectively). The mean duration of SSZ treatment when the first ADR occurred in patients carrying both the NAT1 slow acetylator genotype and the NAT2 slow acetylator genotypes was 8 days (range 3–128 days), shorter than that of 33 days (range 10–450 days) in the carriers of other acetylator genotypes (P = 0.003). No significant differences in the frequencies of non-dose-related ADRs were found among carriers of any NAT1 and NAT2 acetylator genotype combinations (P > 0.05).

Only one patient was identified that experienced time-related ADR and carried NAT1 slow acetylator (NAT1*3/NAT1*3) and NAT2 fast acetylator (NAT2*4/NAT2*6) genotypes.
### Table 1 Distribution of NAT polymorphisms in AS patients and healthy controls

| Alleles/Genotypes/Acetylator genotypes | AS       | HC       | \( \chi^2 \) | \( P \) |
|---------------------------------------|----------|----------|----------------|--------|
| **NAT1 Alleles**                      |          |          |                |        |
| NAT1*4                                | 268      | 261      | 1.55           | 0.21   |
| NAT1*3                                | 101      | 108      | 0.02           | 0.90   |
| NAT1*10                               | 159      | 188      | 1.71           | 0.19   |
| NAT1*11                               | 4        | 3        | -              | 0.72*  |
| Total                                 | 532      | 560      |                |        |
| **NAT1 Genotypes**                    |          |          |                |        |
| NAT1*4/NAT1*4                         | 75       | 65       | 1.78           | 0.18   |
| NAT1*4/NAT1*3                         | 39       | 48       | 0.63           | 0.43   |
| NAT1*4/NAT1*10                        | 77       | 80       | 0.01           | 0.92   |
| NAT1*4/NAT1*11                        | 2        | 3        | -              | 1.00*  |
| NAT1*3/NAT1*3                         | 14       | 14       | 0.02           | 0.89   |
| NAT1*3/NAT1*10                        | 34       | 32       | 0.24           | 0.63   |
| NAT1*2/ NAT1*11                       | 0        | 0        | -              | -      |
| NAT1*10/NAT1*10                       | 23       | 38       | 3.33           | 0.07   |
| NAT1*10/NAT1*11                       | 2        | 0        | -              | -      |
| NAT1*11/NAT1*11                       | 0        | 0        | -              | -      |
| Total                                 | 266      | 280      |                |        |
| **NAT1 Acetylator Genotypes**          |          |          |                |        |
| Fast                                  | 136      | 150      | 0.33           | 0.57   |
| Slow                                  | 130      | 130      | 0.48           | 0.92   |
| Total                                 | 266      | 280      |                |        |
| **NAT2 Alleles**                      |          |          |                |        |
| NAT2*4                                | 310      | 340      | 0.68           | 0.41   |
| NAT2*5                                | 18       | 18       | 0.02           | 0.88   |
| NAT2*6                                | 134      | 129      | 0.69           | 0.41   |
| NAT2*7                                | 70       | 73       | 1.00           | 0.95   |
| Total                                 | 532      | 560      |                |        |
| **NAT2 Genotypes**                    |          |          |                |        |
| NAT2*4/NAT2*4                         | 98       | 110      | 0.35           | 0.56   |
| NAT2*4/NAT2*5                         | 9        | 10       | 0.01           | 0.91   |
| NAT2*4/NAT2*6                         | 70       | 71       | 0.07           | 0.80   |
| NAT2*4/NAT2*7                         | 35       | 39       | 0.07           | 0.79   |
| NAT2*5/NAT2*5                         | 0        | 1        | -              | -      |
| NAT2*5/NAT2*6                         | 6        | 2        | -              | -      |
| NAT2*5/NAT2*7                         | 3        | 4        | -              | -      |
| NAT2*6/NAT2*7                         | 18       | 18       | 0.03           | 0.87   |
| NAT2*6/NAT2*7                         | 22       | 20       | 0.24           | 0.62   |
| NAT2*7/NAT2*7                         | 5        | 5        | 1.00           | 0.04   |
| Total                                 | 266      | 280      |                |        |
| **NAT2 Acetylator Genotypes**          |          |          |                |        |
| Fast                                  | 212      | 230      | 0.53           | 0.47   |
| Slow                                  | 54       | 50       | 1.79           | 0.04   |
| Total                                 | 266      | 280      |                |        |
| **NAT2 fast acetylator genotype plus NAT1*10/NAT1*10** | 17 | 32 | 4.24 | 0.04 |

*Results of Fisher’s exact test; AS = Ankylosing Spondylitis; HC = healthy control; NAT1 = Arylamine N-acetyltransferases 1; NAT2 = Arylamine N-acetyltransferases 2; N = Number; \( \chi^2 \) = Chi-squared test.
This study showed that the NAT genotype appeared not to correlate with the development of AS or the clinical features of AS such as age of onset, duration of disease, joint involvements, incidence of radiological hip involvement, or positive status of HLA-B27. However, the frequency of co-occurrence of the NAT2 fast acetylator genotype and the NAT1*10/NAT1*10 genotype was significantly lower in AS patients than in healthy controls (P = 0.04, OR = 0.53, 95% CI 0.29–0.98). This suggests that the co-occurrence of the NAT2 fast acetylator genotype and the NAT1*10/NAT1*10 genotype is likely to reduce one-half the risk of AS in the Chinese Han population. It was reported that partial linkage disequilibrium exists between the NAT1*10 allele and the NAT2 fast acetylation genotype, and a reduced risk for bladder cancer was identified in carriers of these co-existing genotypes [34]. Because the sample size of our study was relatively small, further investigation should be conducted to reveal the biological significance of the partial linkage disequilibrium between the NAT1*10 allele and the NAT2 fast acetylation genotype in the development of AS.

### Table 2 Clinical features and NAT polymorphisms in 25 AS patients who experienced SSZ-induced ADRs

| ADR types* | Cases | SSZ Dose (g/day) | ADR | Termination of Drug therapy | NAT2 Genotypes | Acetylator genotypes | NAT1 Genotypes | Acetylator genotypes |
|------------|-------|-----------------|-----|-----------------------------|----------------|---------------------|----------------|---------------------|
| Dose-related |       |                 |     |                             |                |                     |                |                     |
| Case 1     | 3.0   | Nausea          | No  | N4/N7                       | F               | F                  | F10/F10        | F                  |
| Case 2     | 3.0   | Nausea, anorexia| No  | N4/N7                       | F               | F                  | F10/F10        | F                  |
| Case 3     | 1.5   | Abdominal pain  | Yes | N2/N6                       | F               | S                  | F10/F10        | F                  |
| Case 4     | 3.0   | Diarrhea        | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 5     | 3.0   | Diarrhea        | No  | N2/N6                       | F               | S                  | F10/F10        | F                  |
| Case 6     | 3.0   | Epigastric discomrt | No | N4/N2                       | F               | F                  | F10/F10        | F                  |
| Case 7     | 1.5   | Epigastric discomrt | Yes| N2/N6                       | F               | S                  | F10/F10        | F                  |
| Case 8     | 1.5   | Increase in transaminases | Yes| N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 9*    | 2.25  | Increase in transaminases | Yes| N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 10    | 2.25  | Dizziness       | No  | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 11    | 1.5   | Dizziness       | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 12    | 1.5   | Dizziness       | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 13    | 1.5   | Dizziness       | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 14    | 1.5   | Dizziness       | Yes | N2/N6                       | F               | F                  | F10/F10        | F                  |
| Case 15    | 3.0   | Dizziness       | No  | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 16    | 1.5   | Dizziness       | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 17    | 2.25  | Leukopenia      | Yes | N2/N6                       | F               | F                  | F10/F10        | F                  |
| Case 18    | 1.5   | Rash            | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 19    | 1.5   | Rash            | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 20    | 1.5   | Rash            | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 21    | 3.0   | Rash            | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 22    | 3.0   | Rash            | Yes | N2/N6                       | S               | S                  | F10/F10        | F                  |
| Case 23    | 2.25  | Oral ulcer      | Yes | N2/N6                       | F               | F                  | F10/F10        | F                  |
| Case 24    | 2.25  | Oral ulcer      | Yes | N2/N6                       | F               | F                  | F10/F10        | F                  |
| Case 25*   | 2.25  | Cacospermia     | Yes | N2/N6                       | F               | F                  | F10/F10        | F                  |

*ADRs were classified into six types: dose-related, non-dose-related, dose-related and time-related, time-related, withdrawal (End of use), and failure of therapy; #Case 9 was observed to have elevated serum liver enzyme levels at day 138 and case 25 had cacospermia at day 450 after the start of SSZ treatment; ADRs = Adverse Drug Reactions; NAT1 = Arylamine N-acetyltransferases 1; NAT2 = Arylamine N-acetyltransferases 2; SSZ = Sulfasalazine.

### Discussion

This study showed that the NAT genotype appeared not to correlate with the development of AS or the clinical features of AS such as age of onset, duration of disease, joint involvements, incidence of radiological hip involvement, or positive status of HLA-B27. However, the frequency of co-occurrence of the NAT2 fast acetylator genotype and the NAT1*10/NAT1*10 genotype was significantly lower in AS patients than in healthy controls (P = 0.04, OR = 0.53, 95% CI 0.29–0.98). This suggests that the co-occurrence of the NAT2 fast acetylator genotype and the NAT1*10/NAT1*10 genotype is likely to reduce one-half the risk of AS in the Chinese Han population. It was reported that partial linkage disequilibrium exists between the NAT1*10 allele and the NAT2 fast acetylation genotype, and a reduced risk for bladder cancer was identified in carriers of these co-existing genotypes [34]. Because the sample size of our study was relatively small, further investigation should be conducted to reveal the biological significance of the partial linkage disequilibrium between the NAT1*10 allele and the NAT2 fast acetylation genotype in the development of AS.
followed by rash, dizziness, and elevated levels of serum liver transaminases. Hematological disturbances (leukopenia) and cacospermia were rarely seen. These characteristics were similar to those reported in previous studies [9,35]. It was also reported that most SSZ-induced ADRs occurred within the first 12 weeks of SSZ treatment [36]. In our study, most ADRs (92%) also occurred within the first 12 weeks. However, one patient (case 9) was observed to have elevated serum liver enzyme levels at day 138 and another patient (case 25) had cacospermia at day 450 after the start of SSZ treatment. This indicates it is important to monitor the ADRs during the first 12 weeks of SSZ treatment. However, liver function tests need to be carried out beyond 12 weeks. Morphological examination and motility tests for sperm are also important for male patients.

The association between single nucleotide polymorphisms (SNPs) and NAT expression has been described in previous reports [11-14]. For example, 341 T > C (I114T) and 590G > A (R197Q) reduce NAT2 catalytic activities, whereas 481C > T (L161L) do not. NAT polymorphisms linked to the differences in the ability to N-acetylate SSZ have been identified [6,10,25-29]. However, it is still not clear whether the genetic variants of NAT1 and NAT2 underlie the patients’ response to SSZ. Previous studies identified a strong association between NAT2 polymorphisms and SSZ-induced ADRs [20,31,37-39] and this association was thought to have an effect on the efficacy of SSZ [26,39]. However, others suggested that NAT1 and NAT2 polymorphisms played no roles in predicting responses to SSZ or related toxicities [40,41]. In our study, the frequencies of overall ADRs and dose-related ADRs of SSZ were higher in the NAT2 slow acetylation genotype group than in the NAT2 fast-type group. The ORs were 2.99 (95% CI 1.26-7.09) and 5.17 (95% CI 1.79-14.92), respectively, indicating that the NAT2 slow acetylator genotype may be a risk factor for ADRs, especially the dose-related ADRs of SSZ. In addition, the prevalence of SSZ treatment terminations owing to overall ADRs or dose-related ADRs was also higher in the NAT2 slow acetylator genotype carriers as compared with that in the NAT2 fast-type carriers (14.8% vs 5.2%, OR = 0.032 and 13.0% vs 1.4%, OR = 0.001). In our study, non-dose-related ADRs only occurred in one patient carrying the NAT2 slow acetylator genotype. Therefore, it is difficult to evaluate the contribution of the NAT2 acetylation genotype to non-dose-related ADRs of SSZ.

The NAT1 function is also widely variable in human populations, although the effects of its genetic polymorphisms are not generally as marked as those of NAT2 [12,13,42]. The current study provided little evidence of correlation between NAT1 acetylator genotypes and the risk of SSZ-induced ADRs by NAT1 single-gene analysis. However, the co-existence of the NAT1 slow acetylator genotype and the NAT2 slow acetylator genotype conferred a 5-fold greater risk for overall ADRs, and a 9-fold greater risk for dose-related ADRs as compared with other acetylator genotype carriers. The termination of SSZ treatment

### Table 3 Associations between NAT acetylator genotypes and SSZ-induced ADRs

|                | NAT2 acetylator genotype | NAT1 acetylator genotype | Co-existence of NAT1 and NAT2 acetylator genotypes |
|----------------|--------------------------|--------------------------|--------------------------------------------------|
|                | Fast         | Slow        | Fast         | Slow        | Fast         | Slow        | Non NAT1 slow plus NAT2 slow | Non NAT1 slow plus NAT2 slow |
| Total ADRs     | 7.1%(15/212) | 18.5%(10/54) | 8.1%(11/136) | 10.8%(14/130) | 26.3%(10/38) | 6.6%(15/228) |
| P*             | 0.013        | 0.45        | <0.001       | 0.07        | <0.001       |
| 95% CI*        | 1.26-7.09    | 0.41        | 2.08-12.37   | 5.07        | 0.002#       |
| Drug therapy termination rate due to ADRs | 5.2%(11/212) | 14.8%(8/54) | 5.9%(8/136) | 8.5%(11/130) | 21.1%(8/38) | 4.8%(11/228) |
| P              | 0.032#       | 0.41        | <0.001       | 0.002#      | <0.001       |
| Drug therapy termination rate due to dose-related ADRs | 1.4%(3/212) | 13.0%(7/54) | 2.2%(3/136) | 5.4%(7/130) | 18.4%(7/38) | 1.3%(3/228) |
| P#             | <0.001#      | 0.21#       | 0.001#       | 0.088       |
| Non-dose-related ADR | 3.3%(7/212) | 1.8%(1/54) | 3.7%(5/136) | 2.3%(3/130) | 2.6%(1/38) | 3.1%(7/228) |
| P#             | 0.58         | 0.51        | 0.001#       | 0.001#      |

*Results of binary logistic regression analysis after adjusting for dose, age, sex, and NSAIDs combination; #Results of Fisher’s exact test; OR = odds ratio; CI = confidence interval; ADRs = Adverse Drug Reactions; NAT1 = Arylamine N-acetyltransferases 1; NAT2 = Arylamine N-acetyltransferases 2; SSZ = Sulfasalazine.
owing to overall ADRs or dose-related ADRs was more commonly seen in AS patients carrying the NAT1 slow and NAT2 slow acetylator genotypes. Additionally, the onset of ADRs was earlier in patients with co-existing the NAT1 slow and NAT2 slow acetylator genotypes than that for other acetylator genotype carriers (8 vs 33 days, \(P = 0.003\)). These findings allow the identification of patients at a possible risk of SSZ-induced ADRs or subsequent terminations of SSZ treatment. It is also important to note that a multi-gene analysis approach is still worthwhile in pharmacogenetic studies even if no positive correlations are found via a single gene analysis.

Similar to the findings of other studies involving Asians such as Chinese and Japanese populations [19,43], our results showed the prevalence of the NAT2 slow acetylator genotype was 20.3% in Han Chinese patients with AS, which is significantly lower than that reported for Western populations (40–70%) [13]. This might explain why SSZ-induced ADRs are much less prevalent among the Chinese (9.4% in our study population) and the Japanese (11.1%) [37] as compared with Western populations (22.7–53.5%) [2,9,35,40]. However, the statistical power is relatively low because of the low frequency of the NAT2 slow acetylator genotype in our study population. It is a challenge to evaluate correlations between NAT polymorphisms and SSZ-induced ADRs without bias. Thus, studies of multi-ethnicity and larger populations are required.

Conclusions
The co-occurrence of the NAT2 fast acetylator genotype and the NAT1*10/NAT1*10 genotype is less frequent in AS patients compared with healthy controls in the Han Chinese population. The NAT2 slow acetylator genotype and co-existing NAT1 and NAT2 slow acetylator genotypes appear to be associated with higher risks of SSZ-induced ADRs.

Abbreviations
NAT: Arylamine N-acetyltransferases; NAT1: Arylamine N-acetyltransferases 1; NAT2: Arylamine N-acetyltransferases 2; AS: Ankylosing Spondylitis; ADRs: Adverse Drug Reactions; SSZ: Sulfasalazine; DMARDs: Disease-Modifying Anti-Rheumatic Drugs; OR: Odds Ratio; CI: Confidence Interval.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
QYZ conceived the study. QYZ, ZDH, and ZYP designed the study. QYZ, ZDH, ZYX, YG, and YPZ collected data and performed data analysis. ZDH drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgments
This study was supported primarily by a grant from the Department of Science and Technology of Guangdong Province (No. 2004B33701014) and Shantou University Medical College (No. LC0401). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author details
1Department of Rheumatology, the First Affiliated Hospital of Shantou University Medical College, No.57 Chang Ping Road, Shantou 515041, Guangdong Province, China. 2Research Unit of Rheumatology, Shantou University Medical College, No.22 Xin Ling Road, Shantou 515041, Guangdong Province, China.

Received: 12 June 2014 Accepted: 10 November 2014
Published: 21 November 2014

References
1. Zeng QY: Ankylosing spondylitis in Shantou, China: 15 years’ clinical experience. J Rheumatol 2003, 30(8):1816–1821.
2. Dougdos M, Maertzel A, Mikyjava M, Amor B: Evaluation of sulphasalazine in the treatment of spondyloarthropathies. Ann Rheum Dis 1992, 51(6):555–558.
3. Cleop DO, Reda DJ, Abdellatif M: Comparison of sulphasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42(11):2325–2329.
4. Schmidt WA, Wirth S, Milleick D, Drost U, Gronrmicke-Hille E: Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies. J Rheumatol 2002, 51(2):159–167.
5. Taggart AGP, McEvoy FHR, Bird H: Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum 1996, 39(8):1400–1405.
6. Tanigawara Y, Kita T, Aoyama N, Gebara M, Komada F, Sakai T, Kowaga M, Hishimata H, Sakoda T, Okumura K: N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull 2002, 25(8):1058–1062.
7. Moum B: Which are the S-ASA compound side effects and how is it possible to avoid them. Inflamm Bowel Dis 2008, 14(Suppl 2):S212–S213.
8. Iott U: Clinical pharmacokinetics of sulfasalazine, its metabolites and other prodrug of 5-aminosalicylic acid. Clin Pharmacokinet 1985, 10:285–302.
9. Plosker GL, Croom KF: Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 2005, 65(13):1825–1849.
10. Kuhn UD, Anschutz M, Schmucker K, Schug BS, Hippius M, Blume HH: Phentypotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. Int J Clin Pharmacol Ther 2010, 48(1):1–10.
11. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans OA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y: Nomenclature for N-acetyltransferases. Pharmacogenetics 1995, 5(1):11–17.
12. Walker K, Ginsberg G, Hattis D, Johns DJ, Goyan KZ, Sonawane B: Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT and NAT2 activity. J Toxicol Environ Health B Crit Rev 2009, 12(0):440–472.
13. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997, 37:269–296.
14. Hein DW: N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol 2009, 5(4):335–366.
15. Pawlik A, Ostanek L, Brzozko I, Gawroska-Siklarz B, Brzozko M, Dobrowska-Zamojcin E: Increased genotype frequency of N-acetyltransferase 2 slow acetylation inpatients with rheumatoid arthritis. Clin Pharmacol Ther 2002, 72(3):319–325.
16. Baranska M, Trzciński R, Dziak A, Rychlik-Sých M, Dudarewicz M, Skretkowicz J: The role of N-acetyltransferase 2 polymorphism in the etiopathogenesis of inflammatory bowel disease. Dig Dis Sci 2011, 56(7):2073–2080.
17. Mikuls TR, Levin T, Gould KA, Yu F, Stahl GM, Byrkte KK, Conn D, Jonas BL, Callahan LF, Smith E, Brasington R, Moreland LW, Reynolds R, Gaffo A, Bridges SL Jr: Interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. Arthritis Rheum 2012, 64(8):2598–2602.
18. Tamer L, Tursen U, Esenkadi G, Ates NA, Ecan B, Yildirim H, Atik U: N-Acetyltransferase 2 polymorphisms in patients with Behcet’s disease. Clin Exp Dermatol 2005, 30(1):56–60.
19. Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, Takahashi H, Kobashi G, Kyushu Sapporo SLE (KYSS) Study Group: Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population. Lupus 2009, 18(7):630–638.
20. Gunnarsson I, Kanerud L, Pettersson E, Lundberg J, Lindblad S, Ringertz B: Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 1997, 36(10):1089–1094.

21. García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Cañete-Vinyals G, Yegor M, Welch B, Chancro J, Charterjee N, Wacholder S, Samanic T, Toró M, Fernández F, Real FJ, Rothman N: NAT2 slow acetylator, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005, 366(9486):649–659.

22. Zhang J, Qiu LX, Wang ZH, Wang JL, He SS, Hu XC: NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2010, 123(3):877–883.

23. Butcher NJ, Minchin RF: Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev 2012, 64(1):147–165.

24. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Eldor J, Hendrickse C, Duncan H, Strange RC: Polyaldenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995, 55(16):3537–3542.

25. Kita T, Sakaeda T, Adachi S, Sakai T, Aoyama N, Hatanaka H, Kasuga M, Okumura K: N-Acetyltransferase 2 genotype correlates with sulphasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol Pharm Bull 2001, 24(10):1176–1180.

26. Kunagai S, Komada F, Kita T, Morinobu A, Ozaki S, Ishida H, Sano H, Matsubara T, Okumura K: N-Acetyltransferase 2 Genotype-Related Efficacy of Sulfasalazine in patients with Rheumatoid Arthritis. Pharm Res 2004, 21(2):324–329.

27. Chen B, Zhang WX, Cai WM: The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur J Clin Pharmacol 2006, 62(5):355–359.

28. Ma JJ, Liu CG, Li JH, Cao XM, Sun SL, Yao X: Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta 2009, 407(1–2):30–35.

29. Daly AK: Pharmacogenomics of adverse drug reactions. Genome Med 2013, 5(1):15.

30. van der Linden S, Valkenburg HA, Cats A: Inclusion in PubMed, CAS, Scopus and Google Scholar

31. Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z: N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol 2007, 21(3):155–158.

32. Tanaka E, Taniguchi A, Urano W, Yamashita H, Kamatani N: Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol 2004, 18(2):233–247.

33. Edwards JR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356(9237):1235–1239.

34. Cassorbi I, Roots I, Brockmoller J: Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 2001, 61(13):5051–5056.

35. Braun J, van der Horst-Bruinisma E, Huang F, Burgos-Vargas R, Waha B, Koenig AS, Freundlich B: Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011, 63(6):1543–1551.

36. Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B: Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986, 293(6544):420–423.

37. Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M, Yamashita H, Saito T, Kamatani N: Adverse effects of sulphasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002, 29(12):2492–2498.

38. Söejima M, Kawauchi Y, Hara M, Kamatani N: Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulphasalazine therapy in patients with rheumatoid arthritis. J Rheumatol 2008, 35(4):724.

39. Sabbagh N, Delaporte E, Marès D, Lo-Guidice JM, Piette F, Broly F: NAT2 genotyping and efficacy of sulphasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 1997, 7(2):131–135.

40. Ricart E, Taylor WR, Loftus EV, O’Hane W, Weishilbourn RM, Tremaine WL, Harmsen WS, Zinsmeister AR, Sandborn WJ: N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulphasalazine in patients with ulcerative colitis. Am J Gastroenterol 2002, 97(3):1763–1768.